Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 10/20 | 0.38 |
| ▸ | CES1 | P23141 | 5/20 | 0.38 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.38 |
| ▸ | ZDHHC7 | Q9NXF8 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.32 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5410821 | 0.76 | CES2 (0.46) | CES2GMNNTP53POLBMAPT | |
| SCHEMBL5407498 | 0.74 | CES2 (0.37) | CES2GMNNTP53POLBMAPT | |
| SCHEMBL6263399 | 0.74 | FAAH (0.37) | MAPTFAAH | |
| SCHEMBL10766442 | 0.72 | CES2 (0.60) | CES2GMNNTP53POLBMAPT | |
| SCHEMBL6266157 | 0.72 | CES2 (0.45) | CES2GMNNTP53POLBMAPT | |
| SCHEMBL15341568 | 0.71 | CES2 (0.58) | CES2GMNNTP53POLBMAPT | |
| SCHEMBL5407492 | 0.70 | CES2 (0.53) | CES2GMNNTP53POLBMAPT | |
| SCHEMBL9879638 | 0.69 | CES2 (0.55) | CES2GMNNTP53POLBMAPT | |
| SCHEMBL6263282 | 0.69 | CES2 (0.51) | CES2GMNNTP53POLBMAPT | |
| SCHEMBL30307640 | 0.69 | LMNA (0.40) | MAPTFAAHZDHHC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060154984-A1 | Therapeutic use of acyl glycerols and the nitrogen- and sulphur- containing analogues thereof | GENFIT (FR) | 2006-07-13 | — | — | US | claimed |
| EP-1596845-A1 | THERAPEUTIC USE OF ACYL GLYCEROLS AND THE NITROGEN- AND SULPHUR-CONTAINING ANALOGUES THEROF | Genfit (FR) | 2005-11-23 | — | — | EP | claimed |
| WO-2004073698-A1 | THERAPEUTIC USE OF ACYL GLYCEROLS AND THE NITROGEN- AND SULPHUR-CONTAINING ANALOGUES THEROF | GENFIT (FR) | 2004-09-02 | — | — | WO | claimed |
| US-7375135-B2 | Fatty acid derivatives; preparation and uses thereof | GENFIT (FR) | 2008-05-20 | — | — | US | disclosed |
| EP-1673338-B1 | FATTY ACID COMPOUNDS, PREPARATION AND USES THEREOF | GENFIT (FR) | 2007-09-19 | — | — | EP | disclosed |
| US-20060252827-A1 | Therapeutic use of of acyglycerols and the nitrogen-and sulphur-containing analogues thereof | GENFIT (FR) | 2006-11-09 | — | — | US | disclosed |
| US-20060154984-A1 | Therapeutic use of acyl glycerols and the nitrogen- and sulphur- containing analogues thereof | GENFIT (FR) | 2006-07-13 | — | — | US | disclosed |
| EP-1673338-A1 | FATTY ACID COMPOUNDS, PREPARATION AND USES THEREOF | Genfit (FR) | 2006-06-28 | — | — | EP | disclosed |
| EP-1596845-A1 | THERAPEUTIC USE OF ACYL GLYCEROLS AND THE NITROGEN- AND SULPHUR-CONTAINING ANALOGUES THEROF | Genfit (FR) | 2005-11-23 | — | — | EP | disclosed |
| US-20040192908-A1 | Fatty acid compounds, preparation and uses thereof | GENFIT (FR) | 2004-09-30 | — | — | US | disclosed |
| WO-2004073698-A1 | THERAPEUTIC USE OF ACYL GLYCEROLS AND THE NITROGEN- AND SULPHUR-CONTAINING ANALOGUES THEROF | GENFIT (FR) | 2004-09-02 | — | — | WO | disclosed |
| WO-2003014073-A1 | FATTY ACID COMPOUNDS, PREPARATION AND USES THEREOF | GENFIT (FR) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252827-A1 | Therapeutic use of of acyglycerols and the nitrogen-and sulphur-containing analogues thereof | SGMS2, SGMS1, AGK | CES2 1719/4885GMNN 206/4885TP53 4498/4885 |
| US-20040192908-A1 | Fatty acid compounds, preparation and uses thereof | FASN, FFAR1, PLIN5 | CES2 1287/4885GMNN 4750/4885TP53 1349/4885 |
| US-20060154984-A1 | Therapeutic use of acyl glycerols and the nitrogen- and sulphur- containing analogues thereof | AGPAT5, HAGH, AGPAT2 | CES2 1234/4885GMNN 574/4885TP53 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.